PMID- 33685195
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1802-5307 (Electronic)
IS  - 0862-495X (Linking)
VI  - 33
IP  - 6
DP  - 2020 Winter
TI  - A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role 
      in primary patients with Hodgkins lymphoma in a real-life cohort.
PG  - 450-457
AB  - INTRODUCTION: In recent years, the positron emission tomography combined with 
      computed tomography (PET/CT) has changed and the treatment approaches in Hodgkins 
      lymphoma (HL) patients have entirely improved. The main idea in several studies 
      is the use of PET/CT and the International Prognostic Score (IPS) protocols in 
      identification of patients within a high-risk group and potential early 
      relapse/refractory disease. MATERIALS AND METHODS: This study was based on PET/CT 
      evaluation and treatment strategies of patients from eight Centers of Hematology 
      in Ukraine. The patients included were newly dia-gnosed with HL and were aged 67 
      years or younger. They received a treatment with ABVD or BEACOPP-14/esc or 
      “switched-regimens” (ABVD + BEACOPP-esc/14, BEACOPP-esc/14 + ABVD). 
      The primary endpoints were to assess a correlation between PET/CT findings at the 
      time of dia-gnosis, response to the therapy and clinical outcome (relapse/death) 
      for patients with early and advanced stages of HL. The secondary endpoints were 
      to evaluate the relationship between IPS and PET/CT findings. RESULTS: The study 
      group included 106 patients. The overall response rate (ORR) was 90.5%. The ORR 
      for patients with stages I-II was 96.5% (55/57) vs. 91% (41/45) for stage III-IV 
      patients. In total, the disease progression occurred in 58.3% (7/12) of PET2+ 
      patients and in 13.3% (12/90) of PET2 patients (P < 0.05). No significant 
      difference was found between the event free survival (EFS) rate and IPS for 
      patients with PET2+ vs. PET2, (log-rank test; P = 0.4). The PET3 status was found 
      in 88.8% (79/89) of the study group patients and 1.2% (10/89) had a PET3+ status 
      (P < 0.05). Using the Cox regression, we confirmed a significant correlation 
      between EFS with PET3 Deauville scale (DS) and IPS. Patients with DS 1-2, DS 3 
      and DS 4-5 had a 1-year event-free survival of 94.4%, 100% and 33%, respectively 
      (HR 0.56; 95% CI 1.07-2.8; P < 0.02). Our multivariable analysis showed no 
      statistically significant correlation between PET2+ and PET3+ status and 
      extranodal involvement or large tumor burden. CONCLUSION: The results of using 
      PET/CT in patients with primary HL demonstrated a high prognostic value of PET at 
      the end of the treatment. In addition, we confirmed the predictive role of IPS 
      prognostic model in the treatment outcome depending on PET status.
FAU - Novosad, Olga
AU  - Novosad O
FAU - Skrypets, Tetiana
AU  - Skrypets T
FAU - Pastushenko, Ian
AU  - Pastushenko I
FAU - Kadnikova, Tetiana
AU  - Kadnikova T
FAU - Gorbach, Oleksandr
AU  - Gorbach O
FAU - Kozlov, Viktor
AU  - Kozlov V
FAU - Mykhalska, Larisa
AU  - Mykhalska L
FAU - Kosinova, Viktoria
AU  - Kosinova V
FAU - Kostiukova, Nina
AU  - Kostiukova N
FAU - Karnabeda, Oksana
AU  - Karnabeda O
FAU - Stratienko, Viktoria
AU  - Stratienko V
FAU - Novikov, Mykola
AU  - Novikov M
FAU - Oliinichenko, Olena
AU  - Oliinichenko O
FAU - Kmetyuk, Iaroslav
AU  - Kmetyuk I
FAU - Karpova, Olga
AU  - Karpova O
FAU - Ashykhmin, Andrii
AU  - Ashykhmin A
FAU - Lukjanec, Olena
AU  - Lukjanec O
FAU - Kriachok, Irina
AU  - Kriachok I
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
TT  - Ukrajinska multicentricka prospektivni studie hodnoty prognosticke role PET/ CT u 
      primarnich pacientů s Hodgkinovym lymfomem v kohortě z realneho 
      života.
PL  - Czech Republic
TA  - Klin Onkol
JT  - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
JID - 9425213
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - ABVD protocol
RN  - BEACOPP protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Dacarbazine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Etoposide/therapeutic use
MH  - Female
MH  - Hodgkin Disease/*diagnostic imaging/*drug therapy/pathology/radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Positron Emission Tomography Computed Tomography
MH  - Prednisone/therapeutic use
MH  - Procarbazine/therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Analysis
MH  - Ukraine
MH  - Vinblastine/therapeutic use
MH  - Vincristine/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Hodgkin's lymphoma - positron emission tomography - prognosis - survival
EDAT- 2020/01/01 00:00
MHDA- 2023/02/25 06:00
CRDT- 2021/03/09 05:38
PHST- 2021/03/09 05:38 [entrez]
PHST- 2020/01/01 00:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
AID - 125206 [pii]
PST - ppublish
SO  - Klin Onkol. 2020 Winter;33(6):450-457.